Pfizer faces pressure on Covid-19 pills; Sanofi's concerns over spies

Taking stock of the drug industry, from the lab to the medicine chest  ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ 

STAT+: Pfizer faces calls to quickly sell more Covid-19 pills to poorer countries By Ed Silverman Pfizer Public Citizen argues inequalities in access to Covid-19 treatments may mirror gaps in vaccine access seen worldwide. Read More STAT+: Fearing spies, Sanofi wants to nix new condo towers that will overlook a Toronto vaccine plant By Ed Silverman Eric Piermont/AFP/Getty Images "From our perspective, this is an issue of national security," said Fabien Marino, a Sanofi vice president who heads the Toronto site. Read More STAT+: Did veteran drug developer Hal Barron accomplish his mission at GSK? By Matthew Herper STAT Hal Barron was brought in to turn around GSK’s labs at a time when the British drug maker was struggling to develop new medicines. Read More Sponsor content by STAT Reports How continuous glucose monitors are transforming diabetes care Continuous glucose monitoring, or CGM, is transforming diabetes care. Where a diagnosis once meant a lifetime of finger pricking and injections, these devices now help achieve less invasive monitoring and treatment for the millions of Americans living with diabetes. With prescriptions of CGMs increasing, the question remains – can these devices become the standard of care? Our latest report looks to answer this question, analyzing our best intelligence on the burgeoning industry of CGM, and examining where the industry is likely to head next. STAT+: Biotech stocks are a dumpster fire. An analyst explains what's going on By Adam Feuerstein and Meg Tirrell and Damian Garde Drew Angerer/Getty Images Jared Holz, the health care equity strategist with Oppenheimer, weighs in on the horrible run for the sector in the markets. Read More Monday, January 24, 2022       1 Exchange Pl, Suite 201, Boston, MA 02109 ©2022, All Rights Reserved. I no longer wish to receive STAT emails Update Email Preferences | Contact Us | View In Browser